The Western IRB, which approved the MDMA/PTSD protocol on July 10, informed us by letter that approval was withdrawn. The revocation was based on secondhand reports of conversations (not on data!) that …
On July 10, we received word that the Institutional Review Board (IRB) had approved MAPS’ MDMA/PTSD study! We can now definitely say that the US study will take place. Dr. Michael Mithoefer still …
MDMA/PTSD protocol submitted to the Western Institutional Review Board (WIRB). Review expected to take 3-5 weeks.
The fourth patient in the Spain MDMA/PTSD dose-response study was treated on November 28, 2001. We have now completed the 50 mgs dose group (3 patients received 50 mgs and 1 received a placebo). The next …
It’s my pleasure to report some excellent news. About 10 AM, Friday, November 2, FDA contacted me to say that MAPS’ MDMA/PTSD protocol was approved. This approval marks the culmination of 16 …
MAPS submitted to the FDA today the protocol for Dr. Michael Mithoefer and Dr. Mark Wagner’s MAPS-supported pilot study into the use of MDMA-assisted psychotherapy in the treatment of patients who …
As part of its submission to FDA of a protocol designed to study the use of MDMA in the treatment of PTSD, MAPS’ commissioned an extensive review of the scientific literature on MDMA. This literature …
A draft of the MDMA/PTSD protocol that MAPS has been working for 2 years to develop, with Dr. Michael Mithoefer and Mark Wagner, Ph.D., at the Medical University of South Carolina, has now been posted …
Investigators: Franz Vollenweider, MD, Alex Gamma, PhD Psychiatric University Hospital – Zrich, Switzerland Sponsors: Swiss National Science Foundation, UBS Science Foundation Psychobiologic studies …
The US Sentencing Commission held an open hearing concerning its proposal to increase penalties on MDMA. Testimony about MDMA opposing the increase was presented by Rick Doblin, Ph.D., David Nichols, Ph.D., …
Investigators: Liechti ME, Gamma A, Vollenweider, FX Sponsors/Funding: Swiss National Science Foundation; Swiss Federal Health Office; Heffter Research Institute References: Psychopharmacology DOI (2001) …
Investigators: Liechti ME, Geyer MA, Hell D, Vollenweider FX Sonsors/Funding: Swiss National Science Foundation; Swiss Federal Health Office; Heffter Research Institute References: Neuropsychopharmacology …
